Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457990 | 0.83 | HTT (0.47) | SMN1; SMN2KDM4EPOLBLMNA | |
| SCHEMBL5466726 | 0.82 | SRC (0.37) | SMN1; SMN2SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL1533618 | 0.79 | SRC (0.58) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL28945095 | 0.75 | SMN1; SMN2 (0.49) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL10387019 | 0.73 | SMN1; SMN2 (0.46) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL6259017 | 0.73 | AKR1C3 (0.57) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL575045 | 0.73 | AKR1C3 (0.57) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL9314030 | 0.73 | ALDH1A1 (0.47) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| SCHEMBL27446830 | 0.72 | AKR1C3 (0.56) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4076278 | 0.72 | AKR1C3 (0.56) | TBXAS1SMN1; SMN2CFTRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149605-A1 | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-28 | — | — | US | disclosed |
| EP-1643988-A1 | SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004105752-A1 | SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149605-A1 | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | HMGCR, CYP46A1, GRHPR | TBXAS1 986/4885SMN1; SMN2 4728/4885CFTR 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.